
Paolo Tarantino/X
Sep 7, 2025, 12:21
Paolo Tarantino Highlights Positive PFS Results from DYNASTY-Breast02 Trial
Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Associate Editor for Breast Cancer at ESMO Open, shared a post on X:
“Press release: positive PFS results from a Chinese phase 3 trial comparing Trastuzumab Pamirtecan (BNT323/DB-1303 – quite similar to T-DXd) to T-DM1 for HER2+ MBC. The DYNASTY-Breast02 trial is testing BNT323 as 1st cytotoxic therapy for HER2-low disease.”
Read the Full Article in BIOTECH.
More posts featuring Trastuzumab on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 7, 2025, 14:05
Sep 7, 2025, 13:10
Sep 7, 2025, 12:35
Sep 7, 2025, 12:14